This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

By Jonathan Ponciano – Mar 13, 2026 at 10:36AM ESTKey PointsDeerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million.Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.As of year's end, the fund reported holding 4,059,695 VERA shares worth $205.58 million.Deerfield Management Company disclosed a buy of 418,538 shares of Vera Therapeutics (VERA 2.77%) in its February 17, 2026, SEC filing, with an estimated transaction value of $14.87 million based on the quarter’s average price.What happenedAccording to a recent SEC filing, Deerfield Management Company increased its holding in Vera Therapeutics (VERA 2.77%) by 418,538 shares during the fourth quarter of 2025. The estimated transaction value, calculated using the period’s average closing price, was approximately $14.87 million. The quarter-end value of the stake increased by $99.77 million, reflecting both the additional shares purchased and changes in the stock price during the period.What else to knowThis was a buy, lifting the stake to approximately 2.6% of the fund’s 13F AUMTop five holdings after the filing:NASDAQ: NUVL: $1.74 billion (25.4% of AUM)NASDAQ: COGT: $321.24 million (4.7% of AUM)NASDAQ: PRAX: $266.25 million (3.9% of AUM)NYSE: CNC: $265.34 million (3.9% of AUM)NASDAQ: VTRS: $251.57 million (3.7% of AUM)As of February 17, 2026, VERA shares were priced at $42.85, up approximately 50% over the past year, compared to a 19% gain in the S&P 500.Company overviewMetricValuePrice (as of market close 2/17/26)$42.85Market capitalization$3.00 billionOne-year price change50%Company snapshotVera’s lead product candidate is atacicept, a fusion protein in Phase IIb clinical trials for immunoglobulin A nephropathy; also developing MAU868, a monoclonal antibody in Phase 2 for BK viremia infections.The firm operates as a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics targeting serious immunological diseases.It serves patients with serious immunological conditions, with a primary focus on the United States healthcare and biotechnology markets.Vera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California. The company differentiates itself through the development of innovative biologic therapies targeting unmet needs in immunological diseases, leveraging advanced protein and antibody platforms. With a robust pipeline and focus on high-burden indications, Vera Therapeutics is positioned to address significant gaps in current treatment options for rare and serious conditions.What this transaction means for investorsVera’s flagship drug candidate, atacicept, targets two proteins known as BAFF and APRIL that drive the production of autoantibodies linked to several kidney and autoimmune diseases, and clinical progress has pushed the program to the regulatory stage. The FDA has granted priority review for the biologics license application for atacicept in IgA nephropathy and set a decision date of July 7, 2026, with a potential commercial launch expected in the middle of this year. The application follows positive Phase 3 data from the ORIGIN study program, which demonstrated meaningful reductions in proteinuria and stabilization of kidney function.Financially, Vera is positioned to reach that milestone. The company ended 2025 with roughly $714.6 million in cash, cash equivalents, and marketable securities, which management says should provide funding through a potential approval and U.S. launch.For long-term investors, this upcoming regulatory decision represents the inflection point that could shift Vera from a clinical-stage biotech into a commercial immunology player, so the next few months will be crucial.About the AuthorJonathan Ponciano is a contributing stock market analyst at The Motley Fool. He has nearly a decade of experience as a financial journalist, most recently as an editor and senior reporter at Forbes focused on markets, technology, and entrepreneurship. Jonathan has also written for Investopedia and the Los Angeles Business Journal. He holds a dual B.A. in Business Journalism and Economics from the University of North Carolina at Chapel Hill and an M.B.A. from Columbia Business School. A North Carolina native now based in New York City, Jonathan has also lived in Mexico City and Los Angeles.CMFjonponcStocks MentionedVera TherapeuticsNASDAQ: VERA$40.12(-2.55%)-$1.05*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.